Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Over $11 million raised since the beginning of 2Q 2025 Cash runway extended into the second half of 2026 In the INVINCIBLE-4 Study, patients receiving INT230-6 prior to the start of standard of care achieved high levels of tumor necrosis in 8 days INT230-6 achieved 100% complete response...